| 2.545 -0.125 (-4.68%) | 12-08 14:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.31 | 1-year : | 3.87 |
| Resists | First : | 2.83 | Second : | 3.31 |
| Pivot price | 2.54  |
|||
| Supports | First : | 2.42 | Second : | 2.17 |
| MAs | MA(5) : | 2.61 |
MA(20) : | 2.52 |
| MA(100) : | 2.47 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.8 |
D(3) : | 63.4 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 4.26 | Low : | 1.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CCCC ] has closed below upper band by 46.6%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.76 - 2.78 | 2.78 - 2.79 |
| Low: | 2.54 - 2.55 | 2.55 - 2.57 |
| Close: | 2.64 - 2.67 | 2.67 - 2.7 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Wed, 03 Dec 2025
TD Cowen Begins Coverage on C4 Therapeutics (NASDAQ:CCCC) - MarketBeat
Wed, 03 Dec 2025
TD Cowen Initiates Coverage on C4 Therapeutics (CCCC) with a Buy Rating | CCCC Stock News - GuruFocus
Tue, 02 Dec 2025
This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Tue, 02 Dec 2025
TD Cowen Initiates Coverage of C4 Therapeutics (CCCC) with Buy Recommendation - Nasdaq
Wed, 26 Nov 2025
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
Tue, 25 Nov 2025
C4 Therapeutics (NASDAQ: CCCC) fireside chat at Evercore conference Dec. 3 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 72.6 (%) |
| Shares Short | 4,850 (K) |
| Shares Short P.Month | 3,990 (K) |
| EPS | -1.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.07 |
| Profit Margin | 0 % |
| Operating Margin | -210.9 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | -26.9 % |
| Gross Profit (p.s.) | -0.85 |
| Sales Per Share | 0.31 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -94 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -1.54 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 8.25 |
| Price to Cash Flow | -2.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|